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Background
Antibodies against the CD4 binding site (CD4bs) in gp120
and the membrane proximal extracellular region (MPER)
of gp41 are associated with broadly neutralization capacity.
While the former have been identified in a large number
of HIV infected individuals, the latter show a much lower
prevalence.
Methods
31 HIV-infected individuals with detectable viremia were
selected for the study. Two samples separated by at least
one year were analyzed for each individual. The presence
of anti-CD4bs was screened using a competitive flow cyto-
metric assay with a CD4 IgG fusion protein. The presence
of anti-MPER antibodies was screened using a sensitive
flow cytometric assay that measures antibody binding to
different cell lines stably expressing two different trun-
cated forms of gp41. These molecules properly expose the
MPER epitope, as assessed by staining with control antibo-
dies 4E10 and 2F5.
Results
Detectable levels of both anti-CD4bs antibodies and anti-
MPER antibodies were observed in plasma samples from
all groups. Of note, most samples showed recognition of
MPER with a strong correlation between the recognition
of the two different forms of truncated gp41 used (r=0.65,
p<0.0001), suggesting that the assay was robust enough for
the detection of these antibodies. However, no correlations
were found between the level of anti-MPER antibodies, the
neutralizing capacity of plasma samples, the viral load and
the CD4 T-cell counts.
Conclusion
Anti-MPER antibodies can be detected in viremic
chronic HIV infected individuals. The level of these
antibodies does not appear to correlate with control of
viremia or clinical progression. These data may suggest
that anti-MPER antibodies are elicited in the course of
HIV infection, but they do not reach the necessary
threshold to be easily detectable or to impact infection.
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